Welcome to our dedicated page for Cardiol Therapeu SEC filings (Ticker: CRDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiol Therapeutics Inc. filings document the formal disclosures of a Canadian life sciences issuer listed on Nasdaq and the TSX. Recent Form 6-K reports furnish press releases and exhibits covering CardiolRx clinical programs, including MAVERIC in recurrent pericarditis and ARCHER in acute myocarditis, as well as CRD-38 development, patent updates, and operating results summarized with audited financial statements and management discussion.
The filing record also documents governance and capital-structure matters, including annual general meeting notices, Class A common share voting mechanics, bought deal private placement terms, underwriting agreements, and warrant indenture provisions. These filings describe the company’s securities, financing arrangements, clinical-development disclosures, and foreign-issuer reporting framework.